Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
RESEARCH TOOLSreports
Holding SLN?
Track your performance easily
SLN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.81 - $27.72
Previous Close$7.92
Volume576.45K
Average Volume (3M)349.01K
Market Cap
$369.55M
Enterprise Value$376.02M
Total Cash (Recent Filing)£54.03M
Total Debt (Recent Filing)£59.18M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Mar 12, 2025EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding46,800,000
10 Day Avg. Volume968,708
30 Day Avg. Volume349,013
Standard Deviation0.22
R-Squared0.07
Alpha0.00701
Financial Highlights & Ratios
Price to Book (P/B)2.89
Price to Sales (P/S)13.60
Price to Cash Flow (P/CF)-9.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$54.75Price Target Upside591.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Silence Therapeutics News
PremiumCompany Announcements
Silence Therapeutics Showcases Promising Phase 2 Results
PremiumCompany Announcements
Silence Therapeutics: Rising Assets Amid Growing Losses
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyZerlasiran demonstrated a highly significant reduction of approximately 90% from baseline in Lp(a) compared to placebo with no safety concerns reported.
Clinical Trial AdvancementThe data support advancement to Phase 3 and that Silence should be able to secure a robust collaboration to bring the program forward.
Drug Tolerability And SafetyZerlasiran continued to be well tolerated through the 48-week dosing period with no serious safety concerns.
Bears Say
Clinical Development RiskRisks include clinical development risk tied to zerlasiran (SLN360) and divesiran (SLN124).
Market And CompetitionCompetitor risk in relevant therapeutic areas presents challenges for SLN.
Stock PerformanceSLN shares have declined by more than 40% since November 15.
---
Ownership Overview
6.10%
Insiders
1.45% Mutual Funds
47.22% Other Institutional Investors
45.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $5.81 and its highest was $27.72 in the past 12 months.
What is Silence Therapeutics’s market cap?
Currently, no data Available
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Mar 12, 2025 which is in 80 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.123 by -$0.117.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -$0.12.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 46,659,940 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.123. Following the earnings report the stock price went down -8.268%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Among the largest hedge funds holding Silence Therapeutics’s share is Woodline Partners LP. It holds Silence Therapeutics’s shares valued at 7M.
---
Silence Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.75 (591.29% Upside)
$54.75 (591.29% Upside)
Blogger Sentiment
Bullish
SLN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 316.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.41%
12-Months-Change
Fundamentals
Return on Equity
-99.23%
Trailing 12-Months
Asset Growth
90.06%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.
---
SLN Company Deck
---
SLN Earnings Call
Q4 2024
0:00 / 0:00
---
SLN Stock 12 Month Forecast
Average Price Target
$54.75
▲(591.29% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering SLN
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
+51.39%
reiterated a buy rating last month
Copying Michael Ulz's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of +51.39% per trade.
---